Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Respira Technologies seeks drug candidates for its nebulizer

By Nancy Crotti | June 4, 2020

(image from Respira Technologies)

Respira Technologies (West Hollywood, Calif.) announced the launch of a pharmaceutical-focused commercial development program for its RespiRx drug-delivery device platform.

RespiRx is a portable, handheld vibrating mesh nebulizer designed for local and systemic treatment and can operate in any position held by the patient. Current-generation nebulizers are gravity-fed, which limits usage and can lead to improper use and/or lower rates of drug-delivery efficacy, according to the company.

RespiRx also has a pre-filled cartridge that includes a disposable piezo element and the drug compound suspended in an aqueous solution. This format is designed to improve convenience and eliminate patient error and misuse due to the lack of proper cleaning. The cartridge is programmable for precise dose delivery and is Bluetooth-enabled for dose delivery tracking, measurement, and electronic medical record data collection for the healthcare provider.

Target indications for the RespiRx include the treatment of asthma, COPD, potential vaccine delivery, pain management, nicotine replacement therapy and investigative new drugs such as inhalable insulin.

“The current landscape of drug delivery platforms lacks the patient focused attributes necessary to address the high rate of patient misuse of daily controller medications, including nebulizers,” said CEO Mario Danek in a news release, “The RespiRx was created to address the patient’s unmet needs for improved care.”

The company is backed by venture firms DG incubation, Evolution VC Partners and Poseidon Asset Management.


Filed Under: Drug Delivery
Tagged With: Respira Technologies
 

Related Articles Read More >

A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Ypsomed Ypsodose patch injector
ten23 health to develop large-volume injectables for Ypsomed’s YpsoDose
Shasqi
Click chemistry breakthroughs drive Shasqi and J&J cancer alliance
Shasqi
Nobel-connected startup Shasqi deepens J&J partnership on CAPAC platform
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE